Treatment of epithelial ovarian cancer
L Kuroki, SR Guntupalli - Bmj, 2020 - bmj.com
Ovarian cancer is the third most common gynecologic malignancy worldwide but accounts
for the highest mortality rate among these cancers. A stepwise approach to assessment …
for the highest mortality rate among these cancers. A stepwise approach to assessment …
Therapeutic strategies to overcome cisplatin resistance in ovarian cancer
M Song, M Cui, K Liu - European journal of medicinal chemistry, 2022 - Elsevier
Ovarian cancer (OC) is one of the most common gynecologic tumors worldwide and one
with the highest mortality. Cisplatin (DDP) is the first platinum-based complex approved by …
with the highest mortality. Cisplatin (DDP) is the first platinum-based complex approved by …
Newly diagnosed and relapsed epithelial ovarian cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up☆
A González-Martín, P Harter, A Leary… - Annals of …, 2023 - annalsofoncology.org
Epithelial ovarian cancer (EOC) represents a heterogeneous spectrum of disease entities at
a clinical, pathological and molecular level. Ovarian cancer is the second most lethal …
a clinical, pathological and molecular level. Ovarian cancer is the second most lethal …
Randomized trial of intravenous versus intraperitoneal chemotherapy plus bevacizumab in advanced ovarian carcinoma: an NRG oncology/gynecologic oncology …
JL Walker, MF Brady, L Wenzel, GF Fleming… - Journal of Clinical …, 2019 - ascopubs.org
PURPOSE To evaluate the impact of two different intraperitoneal (IP) chemotherapy
regimens on progression-free survival (PFS) among women with newly diagnosed …
regimens on progression-free survival (PFS) among women with newly diagnosed …
Phase II Study of WEE1 Inhibitor AZD1775 Plus Carboplatin in Patients With TP53-Mutated Ovarian Cancer Refractory or Resistant to First-Line Therapy Within 3 …
S Leijen, RMJM van Geel, GS Sonke… - Journal of Clinical …, 2016 - ascopubs.org
Purpose AZD1775 is a first-in-class, potent, and selective inhibitor of WEE1 with proof of
chemopotentiation in p53-deficient tumors in preclinical models. In a phase I study, the …
chemopotentiation in p53-deficient tumors in preclinical models. In a phase I study, the …
Recent progress in the diagnosis and treatment of ovarian cancer
D Jelovac, DK Armstrong - CA: a cancer journal for clinicians, 2011 - Wiley Online Library
Epithelial ovarian cancer is the most lethal of the gynecologic malignancies, largely due to
the advanced stage at diagnosis in most patients. Screening strategies using ultrasound and …
the advanced stage at diagnosis in most patients. Screening strategies using ultrasound and …
Latest research and treatment of advanced-stage epithelial ovarian cancer
RL Coleman, BJ Monk, AK Sood… - Nature reviews Clinical …, 2013 - nature.com
The natural history of ovarian cancer continues to be characterized by late-stage
presentation, metastatic bulky disease burden and stagnant mortality statistics, despite …
presentation, metastatic bulky disease burden and stagnant mortality statistics, despite …
Carboplatin plus paclitaxel once a week versus every 3 weeks in patients with advanced ovarian cancer (MITO-7): a randomised, multicentre, open-label, phase 3 trial
S Pignata, G Scambia, D Katsaros, C Gallo… - The Lancet …, 2014 - thelancet.com
Background Carboplatin plus paclitaxel administered every 3 weeks is standard first-line
chemotherapy for patients with advanced ovarian cancer. A weekly paclitaxel schedule …
chemotherapy for patients with advanced ovarian cancer. A weekly paclitaxel schedule …
[HTML][HTML] The systemic treatment of recurrent ovarian cancer revisited
T Baert, A Ferrero, J Sehouli, DM O'donnell… - Annals of …, 2021 - Elsevier
Highlights•Platinum-based chemotherapy remains the most active treatment for ovarian
cancer.•Platinum should not be withheld after response to last platinum and a treatment-free …
cancer.•Platinum should not be withheld after response to last platinum and a treatment-free …
Apatinib combined with oral etoposide in patients with platinum-resistant or platinum-refractory ovarian cancer (AEROC): a phase 2, single-arm, prospective study
CY Lan, Y Wang, Y Xiong, JD Li, JX Shen, YF Li… - The Lancet …, 2018 - thelancet.com
Background Anti-angiogenic therapy combined with chemotherapy could improve the
outcomes of patients with platinum-resistant ovarian cancer. Apatinib is an oral tyrosine …
outcomes of patients with platinum-resistant ovarian cancer. Apatinib is an oral tyrosine …